[HTML][HTML] Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective observational RADOA-registry
E Lindhoff-Last, I Birschmann, J Kuhn… - Thrombosis and …, 2022 - thieme-connect.com
Background Direct oral anticoagulants (DOACs) are increasingly used worldwide. Little is
known so far about their pharmacokinetics in emergency situations. Methods A prospective …
known so far about their pharmacokinetics in emergency situations. Methods A prospective …
Pharmacokinetics and pharmacodynamics of direct oral anticoagulants
B Hindley, GYH Lip, AP McCloskey… - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Introduction Direct oral anticoagulants (DOACs) have overtaken vitamin K
antagonists to become the most widely used method of anticoagulation for most indications …
antagonists to become the most widely used method of anticoagulation for most indications …
Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
AL Sennesael, AS Larock, J Douxfils, L Elens… - Thrombosis journal, 2018 - Springer
Background Serious bleeding events have been frequently described in patients taking
direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma …
direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma …
Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know
The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …
Oral anticoagulation in patients in the emergency department: high rates of off-label doses, no difference in bleeding rates
CM Eschler, BK Woitok, GC Funk, P Walter… - The American journal of …, 2020 - Elsevier
Background Empirically, a significant proportion of patients using direct oral anticoagulation
(DOAC) take off-label reduced doses. We aimed to investigate the prevalence, indications …
(DOAC) take off-label reduced doses. We aimed to investigate the prevalence, indications …
Should we monitor the direct oral anticoagulants?
R Diep, D Garcia - Journal of thrombosis and thrombolysis, 2020 - Springer
The direct oral anticoagulants (DOACs) are a novel class of drugs that have shifted the
paradigm for anticoagulation. DOACs largely obviate the need for laboratory monitoring and …
paradigm for anticoagulation. DOACs largely obviate the need for laboratory monitoring and …
Laboratory tests during direct oral anticoagulant treatment? No
G Di Minno, E Ricciardi, A Scalera - Internal and emergency medicine, 2013 - Springer
The anticoagulant effect of Dabigatran etexilate, Rivaroxaban, and Apixaban is dose-
predictable, steady, and little influenced by diet and drugs [1]. Thus, similar to lowmolecular …
predictable, steady, and little influenced by diet and drugs [1]. Thus, similar to lowmolecular …
[HTML][HTML] Antidotes for patients taking novel oral anti-coagulants
SW Yip, YC Chan - World Journal of Emergency Medicine, 2015 - ncbi.nlm.nih.gov
Novel oral anti-coagulants [NOACs: dabigatran (Pradaxa®, Boehringer Ingelheim,
Germany), rivaroxaban (Xarelto®, Bayer, Germany), apixaban (Eliquis®, Bristol-Myers …
Germany), rivaroxaban (Xarelto®, Bayer, Germany), apixaban (Eliquis®, Bristol-Myers …
Laboratory monitoring of direct oral anticoagulants (DOACs)
C Dunois - Biomedicines, 2021 - mdpi.com
The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …
Management of direct oral anticoagulants for invasive procedures
A Godier, I Gouin-Thibault, N Rosencher… - Journal Des Maladies …, 2015 - europepmc.org
Three new Direct Oral Anticoagulants (DOACs), rivaroxaban, apixaban and dabigatran
etexilate are available on the French market. Management of DOAC-induced bleeding risk …
etexilate are available on the French market. Management of DOAC-induced bleeding risk …